Congratulations to MRFF grant winners Prof. Sue Woolfenden and team

The University of Sydney Prof. Sue Woolfenden, Dr Katarina Ostojic, and their team of chief and associate investigators have been awarded a $1.46million MRFF Grant for Clinician Researchers Applied Research in Health for “Equitable Pathways and Integrated Care in Cerebral Palsy” (EPIC-CP).

Luminesce Alliance is delighted to see that our initial support of Dr Katarina Ostojic has progressed to further recognition of Prof Woolfenden, Dr Ostojic, and the team to address the psychosocial risks of precision medicine and ensure its equitable rollout.

EPIC-CP is a social prescribing intervention co-designed with children and young people with cerebral palsy (the most common physical disability in Australia), their parents/carers, and service providers at three NSW Children’s Hospitals: Sydney Children’s Hospital at Randwick and Children’s Hospital Westmead (SCHN), and John Hunter Children’s Hospital in Newcastle. The initial co-development and piloting of EPIC-CP was supported by the Cerebral Palsy Alliance Research Foundation, Sydney Children’s Hospitals Foundation, and Luminesce Alliance.

To date, EPIC-CP involves standardised identification of unmet social needs in the clinical setting, engagement with a Community Linker to identify and connect patients with appropriate supports and care, and a resource pack of available health, social, disability, and education supports for children and young people with cerebral palsy and their families.

In this grant, the team will conduct a large-scale, randomised controlled trial, with economic and implementation evaluations of EPIC-CP across the three Paediatric Rehabilitation Teams in NSW.

The EPIC-CP team include clinicians, researchers, knowledge translation experts, and consumer investigators with lived experience of cerebral palsy from across Sydney Health Partners , Maridulu Budyari Gumal (Sydney Partnership for Health, Education, Research and Enterprise ), and regional partners.

The funding will contribute towards the research team, Community Linkers, an Aboriginal researcher, economic evaluation, trial statistics, implementation evaluation, and consumer advisor payment for the ongoing effectiveness trial.

The grant is part of nearly $230 million in funding to Australia’s best and brightest researchers to undertake potentially groundbreaking, life changing health and medical research projects, to discover new ways to tackle many of the health and medical issues that impact people every day.

Read more about EPIC-PC here.


About Luminesce Alliance 

Luminesce Alliance is a not-for-profit cooperative joint venture between the Sydney Children’s Hospitals Network, the Children’s Medical Research Institute, the Children’s Cancer Institute, the University of Sydney, and the University of New South Wales Sydney. It has been established with the support of the NSW Government to coordinate and integrate paediatric research.

About University of Sydney 

About us – The University of Sydney

About Cerebral Palsy Alliance 

Cerebral Palsy Alliance is a ground-breaking, global centre of expertise for cerebral palsy research, advocacy, intervention and assistive technology innovation.

As the world’s largest private funder of cerebral palsy research, we bring together a powerful alliance of great minds.  Our research-informed interventions are world-class, our unique accelerator program is unlocking the potential of technology to drive greater inclusion for people with disability, and our voice is a powerhouse for bringing together communities and countries in effecting change.

For over 75 years, we have been driven by our founders’ vision of a future where nothing is impossible for people with cerebral palsy and similar conditions. Today, the 17million+ global cerebral palsy community, together with our 2500+ employees and 150,000+ donors, fundraisers and entrepreneurs, are contributing to solving the next set of impossibilities. To find out more visit

About Sydney Children’s Hospital Foundation

One of the largest and most trusted kids’ health charities in the country, Sydney Children’s Hospitals Foundation exists to help provide all children with access to the best possible healthcare, whenever and wherever they need it. We have been delivering on this promise for the last 35 years, raising millions every year for a collective of two major children’s hospitals, specialised care services, and cutting-edge paediatric research, operating across NSW. A conduit, an enabler, and a mechanism for powerful change, we make sure funds raised go directly to the front line of children’s healthcare – from the hospital wards to the treatment rooms, the research labs to the outreach programs. Together with our Movement of Many we are All in for Kids Health. To find out more visit

Posted in Uncategorized

Towards a new cancer treatment

A chance discovery in a laboratory may lead to an effective new treatment for solid cancers that are hard to reach and treat.

Prof Phil Hogg, Honorary Professor at University of Sydney, Faculty at Centenary Institute’s ACRF Centenary Cancer Research Centre, was testing a new molecule that he had created to target a certain protein involved in cancer. But instead of attaching to the protein, the molecule entered only the dead and dying cells in the tumour.

“We realised this molecule is unbelievably selective – it just doesn’t get into healthy cells,” Prof Hogg says.

In further testing, the new molecule has proven to be exceptionally specific for dead and dying tumour cells both in the laboratory and in humans.

Initially with Luminesce Alliance Innovation in Paediatric Precision Medicine seed funding, Prof Hogg and his team have been investigating whether they can use the dead cell-seeking powers of this molecule to characterise tumours and develop a new treatment approach using targeted radiation.

The problem with theranostics is how to deliver the radioisotopes to the correct cells. This research project was about figuring out how the cell death specific compound could be used to deliver a therapeutic radioisotope called Lutetium-177 to a tumour.  If successful, the cell death specific compound would find and enter the dead and dying cells in a tumour and the accompanying Lutetium-177 radioisotope will then go about killing the neighbouring viable tumour cells.

Professor Hogg’s studies have shown that the cell death specific compound is safe in other organs and is naturally excreted from the body by the kidneys. The radioisotope Lutetium-177 has been widely studied and has been shown to be a safe and effective treatment for prostate and neuroendocrine cancer.

The research results to date have been promising and have led to research funding and may lead to commercial opportunities. The results of the project have also been published in peer-reviewed journal publications (see links below) and presented at cancer research forums.

Results from this project will be used to support further funding applications and commercial development. It is anticipated this research will provide the data required for human biodistribution and dosimetry studies, followed by a Phase 1 dose-escalation clinical trial.

“If successful, it could change the paradigm for treating cancers that are hard to reach and treat”, says Prof Hogg.


Posted in Uncategorized